

Home Page

Donate | Join/Renew | Store | View Cart | Log In | Create Account

SEARCH

SNMMI SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Physicians | Technologists | Scientists | Media | Healthcare Provider | Patients | International

NEWS & PUBLICATIONS | MEMBERSHIP | EDUCATION | MEETINGS & EVENTS | ISSUES & ADVOCACY | QUALITY & PRACTICE | RESEARCH | ABOUT SNMMI

REGULATORY Update

SNMMI Submits Comments to FDA on Compounding 4/4

SNMMI submitted comments to the FDA on draft guidance "Compounding and Repackaging of Radiopharmaceuticals by State-Licensed Nuclear Pharmacies." The society strongly recommends that the FDA work with USP to develop a common understanding of activities defined/involved in the compounding of radiopharmaceuticals and support USP in the public standard setting process.


Molecular Imaging News

March 30, 2017

- PET study sheds light on dopamine imbalance during migraine attacks
- Canadian researchers identify protein in MS patients' brains
- Specialty-trained radiologists find more breast cancer, study shows
- Regular exercise may slow effects of Parkinson's disease
- Report finds drop in paid malpractice claims
- Congress isn't done with health care policy, Republicans say
- Health IT can empower patients in multiple ways

Sign up for SNMMI SmartBrief »

Logo



URL

<https://www.snmmi.org/>

Subject

Nuclear engineering – Digests

Accessibility

Free

Language

English

Publisher

The Society of Nuclear Medicine and Molecular Imaging

Brief History

The Society of Nuclear Medicine and Molecular Imaging (SNMMI), formerly known as the Society of Nuclear Medicine. It started their journey from 1954. In 2012, the society changed its name to the Society of Nuclear Medicine and Molecular Imaging.

Scope and Coverage

SNMMI is a one-stop resource for all nuclear medicine and molecular imaging news. It provides relevant news from the field of nuclear science and related areas on its website. It is a nonprofit scientific and professional organization that promotes the science, technology and practical application of nuclear medicine and molecular imaging. SNMMI represents 19,000

nuclear and molecular imaging professionals worldwide. Members include physicians, technologists, physicists, pharmacists, scientists, laboratory professionals and more. Users can find several types of news like general news, press release, government news etc.

Kind of Information

Each entry (article) available with its title and publishing date. All articles are present with a photograph(s). With each entry related topics are available. An example is given below.

Fluciclovine PET/CT Improves Radiotherapy Targeting for Recurrent Prostate Cancer

March 6, 2017

Reston, Va. – The featured clinical investigation article of the March 2017 issue of *The Journal of Nuclear Medicine* demonstrates that the PET radiotracer fluciclovine (fluorine-18; F-18) can help guide and monitor targeted treatment for recurrent prostate cancer, allowing for individualized, targeted therapy.

“This is the first study of its kind demonstrating changes in post-surgery radiotherapy target design with advanced molecular imaging in recurrent prostate cancer, with no demonstrated increase in early radiotherapy side effects,” explains Ashesh B. Jani, MD, of the Winship Cancer Institute of Emory University, Atlanta, Georgia.

According to the American Cancer Society, one in seven men will develop prostate cancer in his lifetime. In 2017, more than 161,000 new cases of prostate cancer are expected to be diagnosed in the U.S., and about 26,730 deaths from the disease are anticipated.

For the study, 96 patients were enrolled in a clinical trial of radiotherapy for recurrent prostate cancer after prostatectomy. All patients underwent initial treatment planning based on results from conventional abdominopelvic imaging (CT or MRI). Forty-five of the patients then underwent treatment-planning modification (better defining the tumor-targeted area) after additionally undergoing abdominopelvic F-18-fluciclovine PET/CT. No increase in toxicity was observed with this process.

The Emory researchers determined that the inclusion of F-18-fluciclovine PET information in the treatment planning process leads to significant differences in target volumes (the areas to receive radiotherapy). It did result in higher radiation dose delivered to the penile bulb, but no significant differences in bladder or rectal radiation dose or in acute genitourinary or gastrointestinal toxicity.




Figure: Representative example of fluciclovine (F-18) to define target.

These are preliminary results in a three-year study, which hypothesizes that there will be an increase in disease-free survival for patients in the F-18-fluciclovine-modified treatment group over those in the standard treatment group.

This study could have implications beyond prostate cancer, Jani points out, “Our methodology is readily applicable to other novel imaging agents, and it may potentially

facilitate improvement of cancer control outcomes.”

Special Features

- Links to social networking sites like Facebook, Twitter, Google+ and so on. Youtube service also present.
- Contact and feedback option available with proper form.
- A sitemap present.
- Popular posts present.

Arrangement Pattern

The articles are arranged according to publication date wise (Descending order). e.g.:

2017 Hot Trot 5K—Reaching New Heights in the Mile-High City!

Mar 28, 2017 — The 3rd Annual "Hot Trot 5K" run/walk will take place in Denver, CO, on Saturday, June 10, at 7:00 am. Proceeds will support the Professional Development and Education Fund for SNMMI-TS and a local charity. New this year: a virtual option!

SNMMI Social Media Reach Engagement Milestones

Mar 20, 2017 — Today, information is received through a variety of media. What social media excels at is providing immediacy and a network of colleagues. It's evident that these channels provide valuable information, as SNMMI's Facebook page now has more than 12,000 likes, and the SNMMI LinkedIn group has more than 11,000 members!

In Memoriam: Dirk (Dik) J. Kwekkeboom, MD, PhD

Mar 15, 2017 — Dirk (Dik) J. Kwekkeboom, MD, PhD, professor of nuclear medicine at Erasmus University in Rotterdam, The Netherlands, passed away March 8, 2017. An SNMMI member since 1998, he was considered one of Europe's foremost experts on peptide receptor radiotherapy and was a frequent international speaker on neuroendocrine tumor imaging and lutetium-177 octreotate therapy.

New in JNMT

Mar 13, 2017 — The March 2017 issue of "The Journal of Nuclear Medicine Technology" is now available.

Fluciclovine PET/CT Improves Radiotherapy Targeting for Recurrent Prostate Cancer

Mar 6, 2017 — The featured clinical investigation article of the March 2017 issue of "The Journal of Nuclear Medicine" demonstrates that the PET radiotracer fluciclovine (fluorine-18; F-18) can help guide and monitor targeted treatment for recurrent prostate cancer, allowing for individualized, targeted therapy.

New PET Radiotracer Identifies Inflammation in Life-Threatening Atherosclerosis

Mar 1, 2017 — In the featured article of the March 2017 issue of "The Journal of Nuclear Medicine," researchers demonstrate that a new positron emission tomography (PET) radiotracer, gallium-68 (Ga-68)-pentixafor, can quickly and non-invasively identify life-threatening atherosclerotic plaques. The tracer binds to the CXCR4 receptor on inflammatory cells present in atherosclerotic plaques—making it possible to find and treat atherosclerosis early.

Remarks

It helps to read various publications and learn more about nuclear advancement, news etc. that play vital role in nuclear science fields. SNMMI's mission is to improve human health by advancing molecular imaging and therapy. For more than 50 years, SNMMI members have contributed to advances in medical imaging to allow for noninvasive diagnosis, management and treatment of diseases.

Comparable Tools

- [Open Medicine Digest \(https://blogs.biomedcentral.com/on-medicine/tag/open-medicine-digest/\)](https://blogs.biomedcentral.com/on-medicine/tag/open-medicine-digest/)
-

Date of Access

March 31, 2017